Xiao Zheng
Publication Activity (10 Years)
Years Active: 2022-2024
Publications (10 Years): 11
Publications (10 Years): 11
Publications
- Yongqiang Lv, Chaolian Wang, Ruoyu Liu, Shaoxian Wu, Junjun Chen, Xiao Zheng, Tianwei Jiang, Lujun Chen
- Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan XiaXELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
- Yongqiang Lv, Chaolian Wang, Ruoyu Liu, Shaoxian Wu, Junjun Chen, Xiao Zheng, Tianwei Jiang, Lujun Chen
- Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan XiaXELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
- Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan XiaXELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal transduction and targeted therapy 9 (1) (2024)
- Yongqiang Lv, Chaolian Wang, Ruoyu Liu, Shaoxian Wu, Junjun Chen, Xiao Zheng, Tianwei Jiang, Lujun Chen
- Zhang Fang, Xinyi Ding, Hao Huang, Hongwei Jiang, Jingting Jiang, Xiao Zheng
- Zhang Fang, Xinyi Ding, Hao Huang, Hongwei Jiang, Jingting Jiang, Xiao Zheng
- Zhang Fang, Xinyi Ding, Hao Huang, Hongwei Jiang, Jingting Jiang, Xiao Zheng
- You Zhou, Qi Wang, Haifeng Deng, Bin Xu, Yi Zhou, Jian Liu, Yingting Liu, Yufang Shi, Xiao Zheng, Jing Ting Jiang